Prokarium is a biopharmaceutical company that utilizes a proprietary strain of bacteria, ZH9, as a foundation for its microbial immunotherapy platform. This innovative technology harnesses the natural anti-tumor mechanisms of the bacteria to target tumors effectively while overcoming the suppressive tumor microenvironment. Prokarium's approach is designed to activate multiple pathways that elicit robust anti-tumor immunity, providing extensive opportunities for delivering various therapeutic agents. Their lead program focuses on bladder cancer, aiming to transform treatment paradigms in a field that has seen minimal innovation over the past three decades.

In addition to its foundational technology, Prokarium is advancing its Living Cures platform, which employs synthetic biology to create programmable therapeutics. This platform is designed to deliver diverse therapeutic cargo, including the production of therapeutic molecules within the tumor microenvironment and targeted delivery of nucleic acids. Prokarium's commitment to developing off-the-shelf immunotherapies aims to enhance accessibility and effectiveness, particularly for patients underserved by current cancer treatments. The company is also focused on restoring immune responses through its oral immune training agent, which seeks to improve the efficacy of existing immunotherapies for a significant portion of cancer patients who currently do not benefit from them.

United Kingdom

Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.

Prokarium

Company Details